Search Within

Dmitriy Zamarin

  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (28)
  2. Meeting Abstract (23)
  3. Book Section (1)
  4. Guidelines (1)
Groups
  1. Department of Medicine (53)
  2. GDMT, Medicine (53)
  3. Gynecologic Medicine Service (53)
  4. Gynecology Disease Management Team (53)
  5. Hematologic Malignancies, Division of (53)
  6. Solid Tumor Oncology Division (53)

More Groups

People
  1. Roisin O'Cearbhaill (42)
  2. Carol Aghajanian (39)
  3. Rachel Grisham (23)
  4. Alexia Iasonos (22)
  5. Claire Friedman (21)
  6. Jason Konner (21)

More People

Years
  1. 2024 (3)
  2. 2023 (6)
  3. 2022 (9)
  4. 2021 (4)
  5. 2020 (9)
  6. 2019 (7)

More Years

Publications
  1. Gynecologic Oncology (16)
  2. Journal of Clinical Oncology (13)
  3. Clinical Cancer Research (3)
  4. International Journal of Gynecological Cancer (3)
  5. Blood (2)
  6. Cell (2)

More Publications

Publishers
  1. Elsevier Inc. (17)
  2. American Society of Clinical Oncology (15)
  3. American Association for Cancer Research (4)
  4. Lippincott Williams & Wilkins (4)
  5. Nature Publishing Group (3)
  6. American Society of Hematology (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: Final results
    Meeting Abstract

    Grisham, R.; Giri, D.; Henson, M.; Iasonos, A.; Zhou, Q.; McDonnell, A.; Girshman, J.; O'Cearbhaill, R.; Zamarin, D.; Aghajanian, C.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer
    Meeting Abstract

    Liu, Y. L.; Boland, J. L.; Cadoo, K. A.; Friedman, C. F.; Konner, J. A.; O'Cearbhaill, R. E.; Aghajanian, C.; Zamarin, D.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer
    Journal Article

    Liu, Y. L.; Zhou, Q.; Iasonos, A.; Emengo, V. N.; Friedman, C.; Konner, J. A.; O'Cearbhaill, R. E.; Aghajanian, C.; Zamarin, D.
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • TOX is a critical regulator of tumour-specific T cell differentiation
    Journal Article

    Scott, A. C.; Dündar, F.; Zumbo, P.; Chandran, S. S.; Klebanoff, C. A.; Shakiba, M.; Trivedi, P.; Menocal, L.; Appleby, H.; Camara, S.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission
    Meeting Abstract

    O'Cearbhaill, R. E.; Gnjatic, S.; Aghajanian, C.; Iasonos, A.; Konner, J. A.; Losada, N.; Sarasohn, D.; Rasalan, T.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save